Pacific Biosciences
Filed with the SEC on · accession 0001104659-26-125153
PACB filed a 424B5 (prospectus (offering)) with the SEC on Nov 10, 2026. Pacific Biosciences filed a prospectus supplement for an at-the-market (ATM) offering of up to $100 million of common stock through sales agent Allen & Company LLC. The stock moved -5.1% by the first close after the filing.
Pacific Biosciences filed a prospectus supplement for an at-the-market (ATM) offering of up to $100 million of common stock through sales agent Allen & Company LLC. The company will pay up to 3% commission on gross proceeds.
Close before
$2.36
Nov 9, 2026
First close after
-5.08%
$2.24
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for PACB, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PACB?
Click herePACB filed a 424B5 (Shelf registration). Pacific Biosciences filed a prospectus supplement for an at-the-market (ATM) offering of up to $100 million of common stock through sales agent Allen & Company LLC. The company will pay up to 3% commission on gross proceeds.
New shares dilute existing holders and are often sold at a discount to the market price.
The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.
PACB closed at $2.36 before the filing and $2.24 on Nov 10, 2026 (-5.08%).
Get alerts when PACB files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days